TPD & Induced-Proximity Company Directory
This is my subjective list of the biotechs who are focused mainly or solely in pushing their own therapeutic pipelines of TPD & induced-proximity drugs. For details on how this list was compiled, see notes at end.
Targeted Protein Degradation (TPD) company directory
Also now including other Induced Proximity & Bifunctional Therapeutics-Focused Companies - now approaching 90 and still growing
- 76Bio
- https://www.76bio.com/
- Next gen TPD but few details yet...
- https://www.76bio.com/
- A-Alpha Bio
- https://www.aalphabio.com/
- Expanding synthetic biology platform into glue discovery based on huge PPI database from nearly 1Bn datapoints using yeast fusion screening
- https://www.aalphabio.com/
- Accutar Biotech
- https://www.accutarbio.com/
- Multiple potential best in class PROTACs for targets like AR, ER, BTK now in clinic
- https://www.accutarbio.com/
- Ambagon Therapeutics
- https://www.ambagontx.com/
- Using knowledge from Christian Ottmann, Michelle Arkin & Luc Brunsveld, looking to identify molecular glues of 14-3-3- proteins which interact with very large number of partners so could unlock many therapeutic avenues.
- https://www.ambagontx.com/
- Amphista Therapeutics
- https://amphista.com/
- New degrading mechanisms, now disclosed to work via new E3 ligases including DCAF16 with advantages over CRBN, VHL etc
- https://amphista.com/
- Apertor Pharmaceuticals
- https://apertorpharma.com/
- Using modified bacterial macrocycles as glues to induce proximity across a wide range of proteins
- https://apertorpharma.com/
- Arvinas
- https://www.arvinas.com/
- The first dedicated TPD biotech with the most advanced assets in PhIII - with potential approval of lead ER degrader in 2025
- https://www.arvinas.com/
- Automera
- https://automeratx.com/
- Singapore-based autophagy start-up with their own (undisclosed) take on AUTAC design
- https://automeratx.com/
- AUTOTAC Bio
- http://autotacbio.com/
- Korea-based autophagy-based company recruiting p62 receptor into AUTOTACs. Check out Dr Kwon's video on the web site.
- http://autotacbio.com/
- Avilar Therapeutics
- https://avilar-tx.com/
- Extracellular degraders using ASGPR & M6P receptors
- https://avilar-tx.com/
- Biohaven Therapeutics
- https://www.biohaven.com/
- Pre-clinical work on ASGPR-based bivalent degraders (MoDE platform targeting eg IgG or IgA) and antibody-recruiting cytotoxics (ARM platform) including former work from Kleo Pharmaceuticals
- https://www.biohaven.com/
- BioTheryx
- https://www.biotheryx.com/
- Range of PROTACs (including clinical BTK degrader) & glues
- https://www.biotheryx.com/
- Booster Therapeutics
- https://www.boostertx.com/
- Harnessing activators of the 20S proteasome for increased protein clearance from work of Darci Trader
- https://www.boostertx.com/
- C4 Therapeutics
- https://c4therapeutics.com/
- Early CRBN PROTAC & glue company now with multiple clinical programmes
- https://c4therapeutics.com/
- Captor Therapeutics
- https://captortherapeutics.com/
- Poland-based glue & PROTAC company tackling mainly well-known glue targets with a few PROTACs of MCL1 and others
- https://captortherapeutics.com/
- Casma Therapeutics
- https://www.casmatx.com/
- Autophagy-based degraders
- https://www.casmatx.com/
- Cullgen
- https://www.cullgen.com/
- Now clinical phase PROTAC/glue company known for innovating around new degrading mechanisms - multiple claimed new E3 ligases who's scope definition we await with interest
- https://www.cullgen.com/
- Cyclera Therapeutics
- https://cycleratx.com/
- Catalytic degradation of extracellular targets using bispecific biologics with pH-dependent release engaging transferrin receptor to claim CNS potential using CYpHER (CatalYtic pH-dependent Endolysosomal delivery with Recycling)-based agents
- https://cycleratx.com/
- Degron Therapeutics
- https://www.degrontx.com/
- Look like best in class glue company from China going after well known targets though are progressing ELAVL1 project also
- https://www.degrontx.com/
- Dialectic Therapeutics
- https://www.dtsciences.com/
- Single asset company with DT2216 in clinic as a VHL-based, platelet-sparing Bcl-xL degrader with claimed improved window over thrombocytopenia relative to Bcl-xL inhibitors like venetoclax due to low VHL expression in platelets
- https://www.dtsciences.com/
- Differentiated Therapeutics
- https://www.dxtherapeutics.com/
- Molecular dynamics and other computational approaches to find new TPD agents
- https://www.dxtherapeutics.com/
- DraupnirBio
- https://draupnir.bio/
- Degradation of extracellular proteins using a new lysosomal degradation mechanism
- https://draupnir.bio/
- Dunad Therapeutics
- https://www.dunadtx.com/
- New monovalent inhibitors and degraders using covalent expertise from the labs of founder Pat Gunning
- https://www.dunadtx.com/
- EntactBio
- https://entactbio.com/
- Komander, Urbe, Buhrlage et al spinout Inducing proximity to deubiquitinases to trim Ub chains to induce protein stabilisation, signalling etc (peviously Locki)
- https://entactbio.com/
- EpiBiologics
- https://www.epibiologics.com/
- Bispecific antibody-based degraders of extracellular and membrane-associated targets
- https://www.epibiologics.com/
- f5 Therapeutics
- https://www.f5therapeutics.com/
- Molecular glues for novel targets using phenotypic screening approaches
- https://www.f5therapeutics.com/
- Fimecs
- https://www.fimecs.com/en/
- PROTACs, initially for pseudokinases - acquired by RaQualia Pharma March 2024
- https://www.fimecs.com/en/
- FireflyBio
- https://fireflybiologics.com/
- From the Versant team who bought you Monte Rosa comes another ADC meets TPD biotech with Nobelist Carolyn B on board - what's not to love?
- https://fireflybiologics.com/
- Foghorn Therapeutics
- https://foghorntx.com/
- Range of glues and PROTACs directed to targets in chromatin regulation, now in clinical phase
- https://foghorntx.com/
- Frontier Medicines
- https://www.frontiermeds.com/
- Had done E3 ligase work in past but TPD efforts now focused on autophagy-based AUTOTACs
- https://www.frontiermeds.com/
- Gandeeva Therapeutics
- https://gandeeva.com/
- The usual mix of AI to give new glues through proprietary means but with an added dose of cryo-EM to assist in optimisation
- https://gandeeva.com/
- Gate Biosciences
- https://www.gatebio.com/
- Sec61 blockers modulate cytosol to ER processing for selective reduction of secreted proteins
- https://www.gatebio.com/
- General Proximity
- https://www.generalproximity.bio/
- Still fairly stealthy - little info beyond next gen induced proximity
- https://www.generalproximity.bio/
- Genexine (acquired EPD BioTherapeutics)
- http://www.genexine.com/en/our-science/bio-protac
- Use nanobody-based POI binders fused to modified E3 ligases to form bespoke ligases which are delivered to cells as RNA in lipid nanoparticles - interesting approach which could work for any target if delivery challenges can be managed
- http://www.genexine.com/en/our-science/bio-protac
- GluBio Therapeutics
- https://www.glubiotx.com/
- Clinical phase glue company based out of China/San Diego with IKZF1/3 & CK1a assets now in clinic - also tackling usual CRBN targets inclusing WIZ1 & Wee1
- https://www.glubiotx.com/
- GlycoEra
- https://www.glycoera.com/
- Extracellular degrader company using bifunctional glycosylated biologics (G-LyTACs) to direct to lysosomal degradation
- https://www.glycoera.com/
- Halda Therapeutics
- https://haldatx.com/
- Not TPD but another "CrewsCo" with an unusual take on tying up essential proteins selectively in tumor cells to kill them using RIPTACs - very interesting concept to target cytotoxics to tumor cells
- https://haldatx.com/
- Haisco Pharmaceutical Group
- https://en.haisco.com/
- Pharma with established pipeline with foray into BTK PROTAC now in clinic
- https://en.haisco.com/
- Hinova Pharmaceutical
- https://www.hinovapharma.com/en/
- Extensive pipeline with several PROTACs now including AR in clinic
- https://www.hinovapharma.com/en/
- Indupro Therapeutics
- https://www.induprotx.com/
- Bispecific agents inducing proximity including VHH-based agents targeting membrane E3 (REULR) as well as tumor associated proximity antigens
- https://www.induprotx.com/
- Kangpu
- https://www.kangpugroup.com/research_development/pipeline.html
- Looks to be best in class CRBN glue portfolio with antibody-glue conjugates (DACs) coming along also
- https://www.kangpugroup.com/research_development/pipeline.html
- Kesmalea Therapeutics
- https://kesmalea.com/
- Unique chemistry platform to generate new degrading drugs overcoming problems of first generation agents
- https://kesmalea.com/
- Kintor Pharmaceutical
- https://en.kintor.com.cn/
- Dermatology & oncology with topical AR PROTAC in clinic and other degrader programmes including intriging-sounding myc glue
- https://en.kintor.com.cn/
- Kymera
- https://www.kymeratx.com/
- Established clinical phase PROTAC company showing progress outside oncology through immunology pipeline with some exciting targets including STAT6
- https://www.kymeratx.com/
- Laigo Bio
- https://www.laigobio.com/en/
- From the labs of Madelon Maurice, Using SureTACs (bispecific biologics) for using membrane-associated E3s (eg FNR128 etc) for degrading intramembrane targets
- https://www.laigobio.com/en/
- Lycia
- https://lyciatx.com/
- Lysosomal degrader company using LYTACs from Nobelist Carolyn Bertozzi
- https://lyciatx.com/
- Lyterian
- https://lyterian.com/
- Recent entrant to protein homeostasis founded by great team including Ingrid Wertz & Miche Rape
- https://lyterian.com/
- Magnet Biomedicines
- https://magnetbio.com/
- Rockstar glue company founded by Schreiber, Cravatt et al promising rational glue discovery using their TrueGlue platform with tissue-selectivity (cf RIPTAC) as well
- https://magnetbio.com/
- Monte Rosa
- https://www.monterosatx.com/
- Claimed rational glue design with lead GSPT1 & VAV1 degraders now in clinic
- https://www.monterosatx.com/
- Neomorph
- https://neomorph.com/index.html#home
- Glue company with pioneering scientists form Celgene & Novartis group
- https://neomorph.com/index.html#home
- NeoX
- https://www.neoxbio.com/index_en.html
- Computational platform to design new bifunctional degraders (NeoDegraders) of BTK etc
- https://www.neoxbio.com/index_en.html
- Nested Therapeutics
- https://nestedtx.com/
- Included in this list as their lead clinical asset NST-628, is a non-degrading molecular glue which sticks MEK to different RAF isoforms thus inhibiting MAPK signalling with broad anti-tumor effects (though it may not have been designed that way a priori).
- https://nestedtx.com/
- Nurix
- https://www.nurixtx.com/
- BTK degrader franchise but E3 inhibitors and now DACs as well. Moving into autoimmune now
- https://www.nurixtx.com/
- Oerth.bio
- https://www.oerthbio.com/
- Joint venture between Arvinas & Bayer to apply TPD methods to agri applications though presumably will need ultra high potency to keep cost of good down and won't be spraying IMiD derivatives on fields?
- https://www.oerthbio.com/
- Orionis Biosciences
- https://orionisbio.com/
- Mainly cytokine-based therapies but expanding into glues in partnership with pharma
- https://orionisbio.com/
- Origami Therapeutics
- https://origamitherapeutics.com/
- Claim to have platform able to identify protein stabilizers and degraders though are setting sights high by focusing on CNS targets
- https://origamitherapeutics.com/
- Orum Therapeutics
- https://www.orumrx.com/
- Leading degrader-antibody conjugate company using mainly GSPT1 glue conjugates also in protein stabilisation via E3 inhibitors
- https://www.orumrx.com/
- Outrun Therapeutics
- https://outruntx.com/
- April 2024 spinout from Satpal Virdee at Dundee aims to inhibit specific E3 ligases for selective protein stabilization which could be a challenging path to take
- https://outruntx.com/
- Paq Therapeutics
- https://www.paqtx.com/
- Autophagy-based degradation using ATTECs (Autophagasome-tethering compounds)
- https://www.paqtx.com/
- Phoremost
- https://www.phoremost.com/
- A range of approaches to target modulation and glue discovery using microproteins and loop insertion to define binding sites to then set scene for peptide to small molecule switch
- https://www.phoremost.com/
- Photys
- https://www.photys.com/
- Introducing the concept of Phosphorylation-Inducing Chimeric Small Molecules (PHICS) to upregulate signalling pathways - may require highly specific effects for precise pathway modulation
- https://www.photys.com/
- Pin Therapeutics
- https://www.pintherapeutics.com/eng/main/main.html
- Searching for new E3 ligases for glue & PROTAC discovery
- https://www.pintherapeutics.com/eng/main/main.html
- Plexium
- https://www.plexium.com/
- Glue and monovalent degrader discovery across many programmes using neat photocleavable DNA tagged libraries in 88000 picowell plate screening
- https://www.plexium.com/
- Progenra
- https://progenra.com/
- PROTAC and glue company now pivoted to focus on Parkinson's Disease via Parkin/PINK axis
- https://progenra.com/
- Proxidrugs
- https://www.proxidrugs.de/
- Not a biotech as such but a cluster of German universities, led out of Frankfurt, focused on therpaeutic application of TPD
- https://www.proxidrugs.de/
- Proximity Therapeutics
- no website yet, stealth mode
- Stealth so no details except maybe neuro focus - input from some big hitters in the Boston TPD ecosystem
- no website yet, stealth mode
- Proxygen
- https://proxygen.com/
- Rational glue "hunting" from Austria with leading academics as founders./advisors
- https://proxygen.com/
- Ranok Therapeutics
- https://www.ranoktherapeutics.com/
- Enigmatic TPD company advancing unique chaperone-recruiting mechanism to degrade protein with claimed tumor-specific effects. Has been in clinic (still?) - unique mechanism throws up many opportunities and questions.
- https://www.ranoktherapeutics.com/
- Rapafusyn Pharmaceuticals
- https://www.rapafusyn.com/
- Use analogs of rapamycin to find non-degrading glues as ligands for difficult to drug targets
- https://www.rapafusyn.com/
- Salarius Pharmaceuticals
- https://salariuspharma.com/
- Cereblon-based glues of well-known targets but using modified chemistry with deuterium-based platform
- https://salariuspharma.com/
- Seed Therapeutics
- https://seedtherapeutics.com/
- Lilly-founded molecular glue company with lead RBM39 asset nearing clinic
- https://seedtherapeutics.com/
- Sibylla Biotech
- https://www.sibyllabiotech.it/
- A novel protein degradation strategy from Italy acting on folding intermediates rather than mature protein. Interesting.
- https://www.sibyllabiotech.it/
- SK Biopharmaceuticals (formerly ProteoVant - formerly Oncopia - formerly Shaomeng Wang lab U Michigan)
- https://sklslabs.com/
- Shaomeng Wang's work on mainly PROTACs (with a few glues) has been commercialized through Oncopia which was acquired by Protevant which was itself acquired by SK Biopharma but the project still seem to be running
- https://sklslabs.com/
- Solu Therapeutics
- https://solutherapeutics.com/
- Eliminating tumor cells or protumorigenic immune clles by bifunctional antibody-recruiting CyTaCs (Cytotoxicity Targeting Chimera) small molecules to be dosed with antibodies. TicTAC platform also for antibody-mediated half-life extension of small molecules
- https://solutherapeutics.com/
- Stablix
- https://www.stablix.com/
- Recruiting deubiquitinases to stabilize proteins in the antithesis to PROTACs. Likely to be useful for many loss of function disorders if as flexible as TPD though little news more recently
- https://www.stablix.com/
- SyntheX
- https://www.synthexlabs.com/
- Machine learning to find glues to specific E3 ligases. 2022 deal with BMS who know a thing or two about glue discovery but quiet since then.
- https://www.synthexlabs.com/
- TenAcesBio
- http://tenaces.bio/
- 2024 Israeli Newco backed by some big pharma names leveraging ML to find molecular glues which is a familiar recipe in this space - the TenAces secret edge has not yet been disclosed
- http://tenaces.bio/
- Ternarx
- https://www.wehi.edu.au/business-development-and-ventures/success-stories/ternarx/
- Melbourne, Australia-based TPD company with Bekky Feltham & David Komander amongst founders/advisors promising to tackle undruggable transcription factors using new TPD approaches though few details yet
- https://www.wehi.edu.au/business-development-and-ventures/success-stories/ternarx/
- Ternary Therapeutics
- https://www.ternarytx.co.uk/
- Still stealthy but expect a good dose of ML & MD assistance in the search for induced-proximity agents from some ML for TPD veterans
- https://www.ternarytx.co.uk/
- Triana Biosciences
- https://trianabio.com/
- Industrializing glue discovery but few details though recent 2024 deal with Pfizer
- https://trianabio.com/
- TRIMTech
- no website yet but see https://startcodon.co/portfolio/trimtech-therapeutics
- Focussing on degraders using the E3 ligase TRIM21 which is known to enable degradation of aggregated species so could be a complementary way into these targets including some high value neuro areas
- no website yet but see https://startcodon.co/portfolio/trimtech-therapeutics
- Ubiquigent
- https://www.ubiquigent.com/
- Combination of DUB inhibitors and degraders as well as DUBTACs as well - truly DUB-omics
- https://www.ubiquigent.com/
- Ubix
- http://www.ubixtrx.com/
- PROTACs, glues and ADCs against well known targets now in clinic
- http://www.ubixtrx.com/
- Uppthera
- https://www.uppthera.com/
- Korean TPD Co with lead PLK1 PROTAC approaching clinic
- https://www.uppthera.com/
- Vant.ai
- https://www.vant.ai/
- Using structural proteomics and generative AI to find new proximity-modulating drugs (Disclosure - I am on the Vant.ai advisory board)
- https://www.vant.ai/
- Venquis
- https://venquistx.com/
- Monovalent degraders from a microscale TPD outfit. Awaiting updates.
- https://venquistx.com/
- Vicinitas
- https://vicinitas.com/
- Dan Nomura-founded stabilizer company using DUBTACs by recruiting deubiquitinases
- https://vicinitas.com/
- No longer trading: Civetta, Cedilla, Polyprox, Celeris, Siduma
A quick note on how I assess the TPDCo landscape to come up with this list:
I have focused mainly on the biotechs whose main or only focus is advancing a therapeutic pipeline of TPD agents . I have also included any larger companies who are advancing new types of TPD or induced-proximity drugs as a key part of their portfolio.
I have deliberately left out a lot of companies: I know of course that most, if not all, big pharma have active TPD efforts across many areas but this is part of a much larger portfolio so I don’t include them in this analysis. Many biotechs are also now dipping their toe in the TPD waters with perhaps one or two degrader projects in their larger portfolios but I don’t try to include these. Likewise, there are many specialist TPD CROs , but again, I don’t include them in my list otherwise it would get very long indeed.
I acknowledge that my list is somewhat subjective and almost certainly not 100% accurate with companies emerging from stealth or pivoting in or out of TPD all the time but I hope it is useful. However, if you see errors or feel your own company should be added, please let me know using the link below or at enquiries@janusdrugdiscovery.com and I’d be happy to make appropriate updates.
I also highlight that I have had the pleasure of having worked closely with many of the companies on this list but my comments (which are based on publicly-available information only) and the inclusion (or exclusion) from this list is not intended in any way to act as an endorsement, recommendation or other comment on the company strategy or potential.
NB Monovalent degraders are often called molecular glues, MonoDACs, CELMods, NEXMods etc
Bifunctional degraders were initially known as PROTACs but this is now a trademarked term (by Arvinas) so proteolysis-targeting chimeras may be known as BiDACs, Proximity-Inducing Compounds etc
I will call bifunctional degraders PROTAC(TM)s here and acknowledge Arvinas' trademark
© 2023-2024
All rights reserved. Janus Drug Discovery Consulting Ltd
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.